Staged-injection procedure to prevent cement leakage during vertebroplasty -: An in vitro study

被引:12
作者
Wu, Zi-Xiang [1 ]
Wei, Lei [1 ]
Hu, Yun-Yu [1 ]
Wang, Hai-Qiang [1 ]
Wan, Shi-Yong [1 ]
Wang, Jun [1 ]
Han, Yisheng [1 ]
机构
[1] Fourth Mil Med Univ, Xijing Hosp, Inst Orthopaed, Xian, Peoples R China
关键词
osteoporosis; bone morphogenetic protein; fibrin sealant; micro-CT; biomechanics; treatment;
D O I
10.1097/BRS.0b013e3181573976
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Study Design. Fibrin sealant (FS) combined with or without growth factor was used to improve the micro-architectural and biomechanical properties of vertebral body in osteoporotic ovine spine. Objective. To analyze the treatment effects of bovine bone morphogenetic protein (bBMP) combined with FS on osteopenic ovine vertebral architecture, bone mineral density, and biomechanics in vivo. Summary of Background Data. Vertebroplasty and ky-phoplasty were used to treat spinal osteoporosis. They can increase strength of vertebrae physically. However, each has specific disadvantages. bBMP could rapidly increasing bone formation and suppressing bone resorption, but little is known about its effect on ovariectomized-induced osteoporosis. Methods. Six sheep underwent ovariectomy and were placed on a low-calcium diet. Twelve months later, according to Ladin square design, L4-L6 vertebrae in all sheep were randomly assigned to 3 treatment groups: A ( 30 mg bBMP/1.5 mL FS), B (30 mg bBMP) and C (1.5 mL FS). All materials were injected into the assigned vertebra transpedicularly. Animals were killed 3 months after injection, and bone mineral density (BMD), biomechanics, and histomorphometry were assessed. Analysis of variance was used to determine effects of bBMP/FS (alpha = 0.05). Results. The BMD in Group 1 was 17.1% and 14.7% higher than that in Group 2 and Group 3, respectively. The micro-CT reconstruction analysis showed that the density and connectivity of trabecular bone in bBMP/FS treated vertebrae were higher than those in control groups. The mechanical properties (yield stress, ultimate stress, energy absorption, bone modulus) of the vertebrae were also significantly higher. In this study, local bBMP/FS treatment showed a positive trend in improving BMD, histomorphometric parameters, and mechanical strength of osteoporotic vertebra. Slow release of bBMP using FS appeared to be an effective method of protein delivery. Conclusion. The use of bBMP/FS in the treatment of vertebral osteoporosis in an attempt to enhance bone strength merits further study.
引用
收藏
页码:2437 / 2442
页数:6
相关论文
共 43 条
[1]
FIBRIN SEALANT - SUMMARY OF A CONFERENCE ON CHARACTERISTICS AND CLINICAL USES [J].
ALVING, BM ;
WEINSTEIN, MJ ;
FINLAYSON, JS ;
MENITOVE, JE ;
FRATANTONI, JC .
TRANSFUSION, 1995, 35 (09) :783-790
[2]
POTENTIATION OF TRANSFORMING GROWTH-FACTOR (TGF-BETA-1) BY NATURAL CORAL AND FIBRIN IN A RABBIT CRANIOPLASTY MODEL [J].
ARNAUD, E ;
MORIEUX, C ;
WYBIER, M ;
DEVERNEJOUL, MC .
CALCIFIED TISSUE INTERNATIONAL, 1994, 54 (06) :493-498
[3]
BARNES TS, 1998, T 1 EUR C BMP ZAGR C
[4]
BODEN SD, 1995, J BONE JOINT SURG AM, V77, P1404, DOI 10.2106/00004623-199509000-00017
[5]
The use of an osteoinductive growth factor for lumbar spinal fusion .2. Study of dose, carrier, and species [J].
Boden, SD ;
Schimandle, JH ;
Hutton, WC .
SPINE, 1995, 20 (24) :2633-2644
[6]
CENTER PD, 2001, ANN CLIN LAB SCI, V31, P108
[7]
Micro macroporous biphasic ceramics and fibrin sealant as a moldable material for bone reconstruction in chronic otitis media surgery. A 15 years experience [J].
D'Arc, MB ;
Daculsi, G .
JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE, 2003, 14 (03) :229-233
[8]
DAMIEN JS, 2002, SPINE S, V27, P50
[9]
Bisphosphonate treatment affects trabecular bone apparent modulus through micro-architecture rather than matrix properties [J].
Day, JS ;
Ding, M ;
Bednarz, P ;
van der Linden, JC ;
Mashiba, T ;
Hirano, T ;
Johnston, CC ;
Burr, DB ;
Hvid, I ;
Sumner, DR ;
Weinans, H .
JOURNAL OF ORTHOPAEDIC RESEARCH, 2004, 22 (03) :465-471
[10]
Fibrin sealant - A review of its use in surgery and endoscopy [J].
Dunn, CJ ;
Goa, KL .
DRUGS, 1999, 58 (05) :863-886